期刊文献+

人乳头瘤病毒疫苗预防宫颈癌的应用 被引量:10

Application of HPV Vaccines in Preventing Development of the Cervical Cancer
下载PDF
导出
摘要 宫颈癌严重危害女性健康,现已明确人乳头瘤病毒(HPV)感染是其主要致病因素。HPV通过机体的细微损伤入侵,HPV E6和E7癌蛋白中的1种或2种持续表达是高危型HPV感染致瘤的关键所在,检测高危型HPV感染及病毒癌蛋白仍不能有效预防宫颈癌。研究者们正着手研制针对HPV的病毒疫苗,从源头预防HPV感染,以期实现宫颈癌的一级预防。目前已有针对HPV16/18型的二价疫苗Cervarix和针对HPV16/18/11/6型的四价疫苗Gardasil的认证上市,预防性HPV疫苗已在全球范围内推广使用并取得显著效果。新一代预防性HPV疫苗在解决疫苗的成本、持久性和广谱免疫问题上取得突破性进展,宫颈癌有望成为人类抗肿瘤史上第一个可以预防的癌症。综述近年HPV的生物学特性、致病机制及预防性HPV疫苗的应用研究与现状。 Cervical cancer causes serious damage to women′ s health. It is clear that human papillomavirus(HPV)infection is the major pathogenic factor. HPV invades the organism by subtle injures. When E6 or E7 oncoprotein is continous expression in the epithelial tissue, high-risk HPV infections contribute to tumorigenicity. Detection of high-risk HPV infection and virus oncoprotein still cannot prevent cervical cancer effectively. Researchers begin to develop a vaccine against the HPV virus, and to prevent HPV infections from the sources, hoping to achieve the primary prevention of cervical cancer. Currently bivalent vaccine Cervarix against HPV 16/18 and quadrivalent vaccine Gardasil against HPV 16/18/11/16 have been approved for marketing. Prophylactic HPV vaccines have been used widely on a global scale and obtained significant effect. A new generation of prophylactic HPV vaccines have made a breakthrough in solving problems including cost, persistence and broad-spectrum immune. Cervical cancer is expected to become the first preventable cancer in the history of human anti-tumor. This review concentrates on the biological characteristics and pathogenic mechanism of HPV and the current application and situation of prophylactic HPV vaccines.
出处 《国际妇产科学杂志》 CAS 2015年第4期466-469,共4页 Journal of International Obstetrics and Gynecology
关键词 乳头状瘤病毒疫苗 宫颈肿瘤 一级预防 Papillomavirus vaccines Uterine cervical neoplasms Primary prevention
  • 相关文献

参考文献28

  • 1Lu B,Kumar A,Castellsague X,et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women:a systematic review & meta-analysis [J]. BMC Infect Dis,2011,11 : 13.
  • 2Schiffman M,Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer[J]. Cancer Epidemiol Biomarkers Prev, 2013,22(4) : 553-560.
  • 3Faridi R,Zahra A,Khan K,et al. Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer[J]. Virol J,2011,8:269.
  • 4Deligeoroglou E, Giannouli A,Athanasopoulos N,et al. HPV infection: immunological aspects and their utility in future therapy [J]. Infect Dis Obstet Gynecol, 2013,2013 : 540850.
  • 5Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirus-associated malignancies [J]. Expert Rev Vaccines, 2013,12(2): 129-141.
  • 6Erickson BK,Alvarez RD,Huh WK. Human papillomavirus:what every provider should know[J]. Am J Obstet Gynecol, 2013,208 (3): 169-175.
  • 7Pang CL,Thierry F. Human papillomavirus proteins as prospective therapeutic targets[J]. Microb Pathog,2013,58:55-65.
  • 8Barrios K,Celis E. TriVax-HPV:an improved peptide-based therapeutic vaccination strategy against human papillomavirus- induced cancers [J]. Cancer Immunol Immunother,2012,61 (8): 1307-1317.
  • 9李雄雄.有希望成为治疗靶标的人乳头瘤病毒蛋白[J].微生物学免疫学进展,2014,42(2):78-85. 被引量:1
  • 10Jin XW,Lipold L,Sikon A,et al. Human papillomavirus vaccine: safe, effective, underused[J]. Cleve Clin J Med, 2013,80 ( 1 ) : 49-60.

同被引文献86

引证文献10

二级引证文献262

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部